Trial Summary
What is the purpose of this trial?This trial develops and studies how well a patient decision aid works in supporting decision-making about when to start or stop new drugs, join clinical trials, or continue active cancer monitoring for patients with medullary thyroid cancer and their caregivers. Developing a patient decision aid may help patients with medullary thyroid cancer make well-informed decisions about their cancer care and be able to discuss their preferences with their doctors.
Is the treatment in the trial 'Decision Aid for Thyroid Cancer' a promising treatment?The treatment in the trial 'Decision Aid for Thyroid Cancer' is a promising approach because it helps patients make informed decisions about their thyroid cancer treatment. It provides clear information and supports patients in choosing the best option based on their personal values and preferences.12456
What data supports the idea that Decision Aid for Thyroid Cancer is an effective treatment?The available research shows that Decision Aid for Thyroid Cancer helps patients make informed choices about their treatment. It improves their understanding of the medical options and reduces the stress and confusion they feel when deciding on treatments. For example, a study found that using a computerized decision aid increased patients' medical knowledge and made them feel more confident about their decisions regarding radioactive iodine treatment. This suggests that the Decision Aid is effective in helping patients with thyroid cancer make better-informed treatment choices.12346
What safety data is available for the thyroid cancer decision aid treatment?The available research does not directly address safety data for the decision aid treatment itself. Instead, it focuses on the usability, impact on medical knowledge, and decisional conflict reduction of the decision aid for patients with early-stage papillary thyroid cancer considering adjuvant radioactive iodine treatment. The studies highlight the decision aid's role in informing patients and facilitating decision-making, but they do not provide specific safety data related to the treatment.12346
Do I need to stop my current medications for this trial?The trial protocol does not specify whether you need to stop your current medications. It focuses on decision-making support for medullary thyroid cancer patients.
Eligibility Criteria
This trial is for adults with medullary thyroid cancer and their caregivers. Participants must be able to communicate in English, and pregnant patients can join. It's also open to healthcare providers treating this condition. People with cognitive or psychological impairments are not eligible.Inclusion Criteria
I am 18 years old or older.
Treatment Details
The study is testing a decision aid designed to help patients and caregivers make informed choices about starting or stopping medications, joining clinical trials, or continuing with active monitoring of medullary thyroid cancer.
1Treatment groups
Experimental Treatment
Group I: Supportive care (decision aid)Experimental Treatment2 Interventions
Participants use decision aid and complete questionnaires.
Find a clinic near you
Research locations nearbySelect from list below to view details:
M D Anderson Cancer CenterHouston, TX
Loading ...
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
National Cancer Institute (NCI)Collaborator
References
A usability study of a computerized decision aid to help patients with, early stage papillary thyroid carcinoma in, decision-making on adjuvant radioactive iodine treatment. [2019]We tested the usability of a patient-directed decision aid (DA), intended for patients with early stage papillary thyroid carcinoma (PTC) deciding to accept or reject adjuvant radioactive iodine (RAI) treatment. This decision is complicated by uncertainty of the medical evidence relating to potential treatment benefits.
Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer. [2012]Decision-making on adjuvant radioactive iodine (RAI) treatment for early-stage papillary thyroid cancer (PTC) is complex because of uncertainties in medical evidence. Using a parallel, two-arm, randomized, controlled trial design, we examined the impact of a patient-directed computerized decision aid (DA) on the medical knowledge and decisional conflict in patients with early-stage PTC considering the choice of being treated with adjuvant RAI or not. The DA describes the rationale, possible risks and benefits, and the medical evidence uncertainty relating to the choice.
Exploring the relationship between patients' information preference style and knowledge acquisition process in a computerized patient decision aid randomized controlled trial. [2019]We have shown in a randomized controlled trial that a computerized patient decision aid (P-DA) improves medical knowledge and reduces decisional conflict, in early stage papillary thyroid cancer patients considering adjuvant radioactive iodine treatment. Our objectives were to examine the relationship between participants' baseline information preference style and the following: 1) quantity of detailed information obtained within the P-DA, and 2) medical knowledge.
Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial. [2018]Patient decision aids (P-DAs) inform medical decision making, but longer term effects are unknown. This article describes extended follow-up from a thyroid cancer treatment P-DA trial.
What do patients want to know about surgery for low-risk thyroid cancer? A qualitative study. [2023]Shared decision-making about treatment for low-risk thyroid cancer requires patients and surgeons to work together to select treatment that best balances risks and expected outcomes with patient preferences and values. To participate, patients must be activated and ask questions. We aimed to characterize what topics patients prioritize during treatment decision-making.
Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing. [2023]Patient decision aids (PtDAs) are structured clinical tools that facilitate shared decision-making. Two important treatment decisions for patients with differentiated thyroid cancer (DTC), which could benefit from PtDAs, are as follows (1): the extent of surgery decision in patients with low-risk DTC and (2) the decision to start or delay starting the treatment with tyrosine kinase inhibitors (TKIs) in patients with advanced tumors.